Update on the Cardiac Safety of Moxifloxacin

Cardiac safety was compared in patients receiving moxifloxacin and other antimicrobials in a large patient population from Phase II–IV randomized active-controlled clinical trials. Moxifloxacin 400 mg once-daily monotherapy was administered orally (PO) or sequentially (intravenous/oral, IV/PO). Acro...

Descripción completa

Detalles Bibliográficos
Autores principales: Haverkamp, Wilhelm, Kruesmann, Frank, Fritsch, Anna, van Veenhuyzen, David, Arvis, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480699/
https://www.ncbi.nlm.nih.gov/pubmed/22873499
http://dx.doi.org/10.2174/157488612802715735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480699/
https://www.ncbi.nlm.nih.gov/pubmed/22873499
http://dx.doi.org/10.2174/157488612802715735

Ejemplares similares